Psoriasis

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP. This trial is a phase 2a, double-blind study focusing on this skin condition characterized by pustules on the palms and soles. The main goal is to see how well delgocitinib cream improves symptoms over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice a day for 16 weeks, while the other group will use a matching vehicle cream twice daily for the same duration. The study includes a total of approximately 18 weeks for each participant, involving around 9 visits. The trial compares the active cream to the placebo cream to assess efficacy and safety. During the study, participants will attend scheduled visits to monitor their condition and collect data on skin symptoms, pustule counts, and quality of life measures. Researchers will assess the improvement in PPP severity using specific scales such as the PPP Area and Severity Index PPPASI. Safety is monitored through reports of any treatment-emergent side effects. Overall participation lasts about 18 weeks, including screening and treatment phases.

Researchers are evaluating the safety and effectiveness of a drug called D-2570 for adults with moderate to severe plaque psoriasis. This randomized, double-blind, placebo- and active-controlled clinical trial is conducted across multiple centers and includes patients aged 18 to 70 years. The study aims to compare different doses of D-2570 with placebo and another drug, BMS-986165, to understand how well D-2570 works and its safety profile. Participants will receive different doses of D-2570, BMS-986165, or a placebo tablet. The treatment period lasts 16 weeks after enrollment. Throughout the study, both participants and investigators remain unaware of which treatment is given to ensure unbiased results. Blood samples will be collected at scheduled times for pharmacokinetic and pharmacodynamic analysis to monitor how the drug behaves in the body. During the study, participants will attend regular visits for safety and efficacy assessments, including physical exams and laboratory tests such as blood chemistry and urinalysis. The main outcome measured is the treatments impact on plaque psoriasis over 16 weeks, with safety monitored through an average of 28 weeks until study completion. Participants will also have a safety follow-up after treatment ends to support ongoing monitoring throughout the study duration.

Researchers are evaluating the dose-effect relationship of TQH3906 capsules compared to placebo in treating active Psoriatic Arthritis PsA. This Phase II, randomized, double-blind, placebo- and active drug-controlled clinical trial aims to measure the proportion of participants achieving a 20% improvement in arthritis symptoms by Week 12, using the American College of Rheumatology ACR20 criteria as the primary endpoint. Participants are randomly assigned to receive one of several oral treatments daily from Day 1 to Day 85 either 24 mg or 16 mg of TQH3906 capsules, placebo capsules matching TQH3906, or 5 mg tofacitinib citrate tablets. The treatments are administered in the morning while fasting, with tofacitinib also taken at bedtime. This study evaluates efficacy and safety across these groups over 12 weeks of treatment. During the study, participants are assessed at multiple timepoints for improvements in arthritis symptoms ACR20, ACR50, ACR70 and psoriasis severity PASI 75 and PASI 90. Blood samples are collected to evaluate drug levels and immune markers at baseline and Weeks 2, 4, 8, and 12. Safety is monitored continuously through adverse event reporting up to 28 days after the last dose. The total study duration per participant is approximately 12 weeks of treatment plus follow-up.

Researchers are evaluating the long-term safety of subcutaneous guselkumab injections in children with moderately to severely active ulcerative colitis, Crohns disease, or juvenile psoriatic arthritis. This Phase 3 study focuses on pediatric participants who have previously been treated with guselkumab and will continue therapy in this extension study to monitor safety over an extended period. Participants who completed dosing in one of three primary pediatric guselkumab studies and are deemed by their investigator to benefit from continued treatment will join this long-term extension. Guselkumab is administered as a subcutaneous injection either every 8 weeks or every 4 weeks, depending on prior study assignment and clinical status. Some participants may switch dosing frequency once during the extension before unblinding, after which dosing aligns with their original regimen. Dose adjustments are restricted based on the primary study they came from. During the study, participants will receive guselkumab injections regularly and be monitored for treatment-emergent adverse events for up to nearly seven years. Researchers will assess safety outcomes through ongoing clinical evaluations over this time. Parents or legal representatives provide consent for children to participate, and children capable of understanding the study will give assent. The total participation duration may extend up to six years and nine months, allowing long-term safety data collection.

Researchers are studying how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study is divided into two parts Part A includes both children and teenagers, while Part B includes only children. Initially, only teenagers who meet the study requirements can participate, with children joining after sufficient information is collected from other studies. Participants in Part A will be randomly assigned to receive either zasocitinib or a matching placebo daily for the first 16 weeks, followed by open-label zasocitinib treatment until the study ends. In Part B, all children will receive zasocitinib throughout the study. The treatment doses for children will be based on their weight, and adolescents will receive a fixed dose. The study lasts up to 4 years and 2 months, including screening, treatment, and safety follow-up periods. During the study, participants will visit the study site multiple times for assessments. Researchers will measure improvements in skin condition using tools like the Static Physicians Global Assessment and Psoriasis Area and Severity Index at Week 16 and throughout the open-label period. Safety and drug levels in the body will also be monitored. After treatment, there is a 4-week safety follow-up. Overall, participants will be involved for up to 217 weeks, including screening, treatment, and follow-up.

Researchers are investigating personalized precision medicine for adults aged 18 to 75 with psoriasis or psoriatic arthritis. This multi-center randomized clinical trial compares a prescreen strategy-based biologics selection using immune cell biomarkers versus standard guideline-based biologics treatment. The study also explores cardiovascular biomarkers to understand disease impact and treatment effects. Participants are randomly assigned to one of two groups a strategic group where biologics are selected based on individual immune cell screening and biomarker scores, and a standard group receiving biologics per current guidelines without prescreening. Biologics studied include adalimumab, etanercept, certolizumab pegol, golimumab, ustekinumab, secukinumab, ixekizumab, bimekizumab, and brodalumab. Blood samples are cultured to analyze cytokine responses, with follow-up visits scheduled at multiple intervals up to 72 weeks, extending up to 3 years if needed. Participants undergo clinical assessments including Psoriasis Area and Severity Index PASI, joint counts, Disease Activity in Psoriatic Arthritis DAPSA score, Dermatology Life Quality Index DLQI, and body surface area affected. Cardiovascular health is monitored by measuring internal carotid artery thickness at 6 months, 1 year, and 2 years. Researchers also collect data on pruritus and cytokine levels to evaluate treatment effects. Safety and efficacy outcomes are assessed regularly throughout the study period, with extended follow-up for up to 5 years.

Researchers are evaluating an experimental medication called WD-890 compared to a placebo in adults with moderate to severe plaque psoriasis. The study focuses on understanding how well WD-890 works and its safety for treating this skin condition. It is a phase 3 trial involving participants diagnosed with plaque psoriasis for at least six months and meeting certain severity criteria. Participants will be randomly assigned to receive either WD-890 tablets or placebo tablets, both taken orally. The trial is designed as a parallel, double-blind, placebo-controlled study, where neither participants nor researchers know who is receiving which treatment. Treatment and assessments will occur over a period of up to 52 weeks. During the study, participants will be regularly assessed for skin improvement using tools like the Physicians Global Assessment score and Psoriasis Area Severity Index at various weeks up to week 52. Quality of life related to dermatology will also be measured. Safety and treatment effects will be monitored through scheduled visits and evaluations throughout the study period.

Researchers are conducting a phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate camoteskimab in adults with moderate-to-severe atopic dermatitis. The study includes both treatment-naive participants and those who have had an inadequate response to previous biologic therapies, aiming to assess the effectiveness and safety of camoteskimab for this condition. The study has two parts. In Part 1, lasting 24 weeks, participants are randomly assigned to receive one of three doses of camoteskimab or a placebo, all given by subcutaneous injection. In Part 2, which is an extension period, all participants will receive camoteskimab. This design allows comparison of different doses and the placebo before all receive the active treatment. Participants will undergo regular assessments including evaluation of eczema severity, body surface area affected, and itch intensity using specific scales like the Eczema Area and Severity Index EASI and Peak Pruritus Numerical Rating Scale PP-NRS. Researchers will monitor changes from baseline over 24 weeks. Safety and adherence will be closely followed throughout the study, which is planned to continue until April 2028.

Researchers are evaluating the efficacy and safety of QL2106 injection compared to Tremfya in patients with moderate to severe plaque psoriasis. This Phase 3, multicenter, randomized, double-blind, parallel, and active-controlled study plans to enroll 318 participants to better understand treatment effects in this population. Participants will be randomly assigned in equal numbers to receive either QL2106 injection or Tremfya. Both treatments are given by subcutaneous injection at Week 0, Week 4, and then every 8 weeks. The recommended dose for both is 100 mg. This study uses a quadruple blinding method to maintain objectivity. Throughout the study, researchers will assess the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index PASI-75 at Week 16. Participants will be monitored for safety and treatment response during the trial. The study is expected to continue until February 2028, with participants involved in regular visits according to the treatment schedule for assessment and care.

Takayasu arteritis TAK is a rare chronic inflammatory disease affecting arteries, and there is no widely accepted effective treatment strategy. Researchers classify TAK patients into three severity levels mild, moderate, and severe. This study focuses on severe TAK patients and compares two biological agents, tocilizumab and adalimumab, to find which treatment may provide better intervention outcomes in this group. The study randomly assigns severe TAK patients to receive either tocilizumab at a dose of 8mgkg intravenously every four weeks or adalimumab at 40mg biweekly by injection for 24 weeks. Patients start with prednisone at 40mg daily, tapered gradually over months, and treatment adjustments are made if disease relapse occurs. After 24 weeks, if remission is not achieved, patients switch to the other biological agent for an additional 24 weeks. Participants are monitored throughout treatment and follow-up for disease remission using clinical and laboratory assessments. Researchers track disease relapse, vascular progression through angiographic exams, prednisone dose reduction, and quality of life changes using questionnaires over a total of 48 weeks. The primary outcome is disease remission at 24 weeks. Safety and disease activity are closely observed during the study.